Aldeyra Therapeutics, Inc.
reproxalap
dry eye disease
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for reproxalap in dry eye disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“disclosed (ii) Aldeyra’s abbreviated interpretations of the U.S. Food & Drug Administration positions on the primary endpoints for the reproxalap clinical trials, as well as the Aldeyra positions on the primary endpoints”